Please note that the details of this Challenge are no longer open. This challenge is closed and is no longer accepting new submissions. You can:
Challenge <p> Seeking a Novel Disease or Indication for a Potent and Selective GPR68 (OGR1) Antagonist</p>

Seeking a Novel Disease or Indication for a Potent and Selective GPR68 (OGR1) Antagonist

Award:  varies
Deadline: Closed
Active Solvers: 163
Posted: Apr 12 2017
Challenge ID: 9933989
Share Challenge Share

Boehringer Ingelheim is looking for a partner that can identify novel and relevant disease indications for a potent and selective preclinical GPR68 (ORG1) antagonist. 

This is an electronic Request-for-Partners (eRFP) Challenge; the Solver will only need to submit a written proposal to be evaluated by the Seeker with the goal of establishing a collaborative partnership.



Recently, the OGR1-family G protein-coupled (GPCR) receptor, GPR68 (also known as OGR1) has been implicated in pH-sensing homeostasis and appears to regulate inflammatory processes in immune and non-immune cells. Studies using genetic approaches have linked GPR68 signaling to multiple cellular functions, including the production of pro-inflammatory and tissue remodeling mediators, osteoclastogenesis, wound repair, epithelial barrier function and tumor genesis. In addition, GPR68 deficient mice have been shown to be protective in several autoimmune, inflammatory and tumor models of disease. Although GPR68 may contribute to the pathogenesis of chronic inflammatory diseases, pharmacological proof of concept is still lacking. Therefore, there is a need to further understand the molecular interplays between GPR68 signaling and disease driving pathways. 

Boehringer-Ingelheim has developed an unprecedented, potent and selective GPR68 antagonist. This tool compound combines unique selectivity and pharmacokinetics (PK) properties that are further described in detail and made available to the Solvers in the Challenge Description section. Additional compounds having differentiated properties and pharmacological profiles may also be available for sharing on request. 

Boehringer Ingelheim believes that this unique preclinical tool compound has a great potential beyond the therapeutic settings that its scientists are currently focusing upon. Therefore, this Challenge invites scientists around the world to submit novel concept proposals. Solvers should submit proposals describing the use of the compound for validation of mechanisms and pathways in disease-related models that can lead to new therapeutic indications and/or target hypothesis. This is also a unique opportunity for selected Solvers to have free of charge access to the compound in the amounts required to conduct the proposed preclinical research work. 

This is an electronic Request-for-Partners (eRFP) Challenge. Solvers will write a preliminary proposal containing only NON CONFIDENTIAL information (about 2-5 pages and contact details) to be evaluated by Boehringer Ingelheim. Upon completion of the Challenge, the Seeker may contact selected Solvers with the goal of discussing the exact terms, scope of work, and duration of the joint partnership for the implementation of the research work submitted to the Challenge. 

NOTE: Only proposals from Solvers who have the ability to work as a collaboration partner will be considered. 

Submissions to this Challenge must be received by 11:59 PM (US Eastern Time) on June 12, 2017. 

Late submissions will not be considered


Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales. 

Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects such as the “Making More Health” initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees’ different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does.  

More information about Boehringer Ingelheim can be found on or in our annual report:

What is InnoCentive?
InnoCentive is the global innovation marketplace where creative minds solve some of the world's most important problems for cash awards up to $1 million. Commercial, governmental and humanitarian organizations engage with InnoCentive to solve problems that can impact humankind in areas ranging from the environment to medical advancements.

What is an eRFP Challenge?

eRFPs allow Seekers to submit Requests for Proposals for a partner or supplier to provide materials or expertise to help solve a business challenge to the InnoCentive Solver community. This global community includes organizations and individuals, such as contract research organizations, scientists, university researchers, and technology companies.

After a Solver submits an eRFP response, the Seeker evaluates the responses to determine which Solver(s) to contact for further business discussions. With eRFPs, the Solver must not provide any confidential information in the eRFP response. If your eRFP response is selected, you negotiate the terms of the contract (including scope of work, tasks and duration) directly with the Seeker.

This Challenge type does not require Intellectual Property (IP) transfer. However, sometimes Challenges of this type do request that certain IP arrangements be made should a partnership be formed.

Share This Challenge
InnoCentive Trust Partners